Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Nina HelbekkmoNorwegian Lung Cancer Study Group

Abstract

There is no consensus regarding chemotherapy to patients with advanced NSCLC (ANSCLC) and performance status (PS) 2. Using data from a national multicenter study comparing two third-generation carboplatin-based regimens in ANSCLC patients, we evaluated the outcome of PS 2 patients. The 123 PS 2 patients were compared to 309 PS 0/1 patients regarding survival, quality of life (QOL) and treatment toxicity. PS 2 patients had lower haemoglobin, lower global QOL and more pain, nausea/vomiting and dyspnea at inclusion. 68% of PS 2 patients received three chemotherapy courses vs. 85% in the PS 0/1 group (P<0.01). Median and 1-year survival were lower in the PS 2 group, 4.5 vs. 8.9 months and 10% vs. 37% (P<.01). More PS 2 patients needed blood transfusions (P=0.03) and hospitalization (P<0.01). In contrast, PS 2 patients had better relief of pain and dyspnea, and tended to a better global QOL and did not experience more leucopoenia, infections or bleeding. Despite shorter survival, treatment toxicity was acceptable and PS 2 patients achieved better improvement of pain and dyspnea and tended to better global QOL when compared to PS 0/1 patients.

References

Jan 1, 1986·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C RuckdeschelS Vogl
Dec 1, 1982·American Journal of Clinical Oncology·M M OkenP P Carbone
Jan 11, 2002·The New England Journal of Medicine·Joan H SchillerUNKNOWN Eastern Cooperative Oncology Group
Aug 31, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Paris KosmidisMeletios Dimopoulos
Aug 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·V AlberolaUNKNOWN Spanish Lung Cancer Group
Oct 29, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Egbert F SmitUNKNOWN European Organization for Research and Treatment of Cancer Lung Cancer Group
Mar 5, 2004·Annals of Oncology : Official Journal of the European Society for Medical Oncology·C GridelliF De Marinis
Dec 22, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francesco PerroneCesare Gridelli
Dec 28, 2005·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Thomas E StinchcombeMark A Socinski
Feb 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Corey LangerUNKNOWN Eastern Cooperative Oncology Group
Apr 6, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Paris A KosmidisHaralampos P Kalofonos
Jun 7, 2007·Journal of the National Cancer Institute·Andrea ArdizzoniUNKNOWN CISCA (CISplatin versus CArboplatin) Meta-analysis Group
Aug 11, 2007·The European Respiratory Journal·J P SculierUNKNOWN European Lung Cancer Working Party

❮ Previous
Next ❯

Citations

Mar 2, 2011·Journal of Oncology Practice·Shalini K VinodGeoff P Delaney
Jul 23, 2014·The Journal of Molecular Diagnostics : JMD·Yi-Lin ChenChung-Liang Ho
Mar 11, 2009·Acta Oncologica·Nina HelbekkmoUNKNOWN Norwegian Lung Cancer Study Group
Nov 4, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Dale HardyXianglin L Du

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.